| 摘要 |
Human cancer is diagnosed/monitored by measuring the levels of N-[9-( beta -D-ribofuranosyl)purin-6-ylcarbamoyl]-L-threonine (t6A), in a physiological fluid specimen of a subject by a quantitative immunoassay that employs a monoclonal anti-t6A antibody and comparing that level to the level of t6A that occurs in corresponding physiological fluid of normal subjects to determine whether the former is substantially elevated over the latter or by comparing that level to the level of t6A present in specimens taken from the subject at different times.
|
